K082898 · Amedica Biotech, Inc. · NGL · Dec 19, 2008 · Clinical Toxicology
Device Facts
Record ID
K082898
Device Name
AMEDICA DRUG SCREEN TEST CUP
Applicant
Amedica Biotech, Inc.
Product Code
NGL · Clinical Toxicology
Decision Date
Dec 19, 2008
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 862.3650
Device Class
Class 2
Indications for Use
The Amedica Home Drug Test Cup is an in vitro diagnostic test for the rapid detection of the following drugs in human urine. This test is intended for over-the-counter (OTC) consumer use as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory testing- the second step in the process, is provided in the package labeling. Tests for prescription drugs will yield preliminary positive results when prescription drugs are ingested, even at or above therapeutic doses. There are no uniformly recognized drug cutoffs for barbiturates, benzodiazepine, and tricyclic antidepressants in urine. The multi-drug of abuse urine test device shows the drug was or was not present at the cutoff level. This test provides only a preliminary result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or High Performance Liquid Chromatography (HPLC) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.
Device Story
Amedica Home Drug Test Cup; lateral flow immunoassay for qualitative detection of 12 drugs/metabolites in human urine. Device consists of a collection cup with integrated reagent strips for each analyte; includes temperature strip for sample validity. Principle: competitive binding; drug in sample competes with immobilized drug-specific conjugate for antibody-coated particles. Presence of drug above cutoff prevents colored line formation at test region; control line indicates proper migration. Intended for OTC consumer use (e.g., parents); provides preliminary results. Positive results require confirmation via GC/MS or HPLC. User reads visual lines on cup; temperature strip verifies sample temperature. Benefits: provides consumers with rapid, preliminary information regarding drug presence; facilitates subsequent professional confirmatory testing.
Clinical Evidence
No clinical data provided; device relies on analytical performance characteristics for drug detection.
Technological Characteristics
Lateral flow immunochromatographic assay; competitive binding principle. Device is a multi-drug collection cup containing specific reagent strips for 12 analytes. Includes integrated temperature strip. No electronic components or software. Visual readout of colored lines.
Indications for Use
Indicated for OTC consumer use for rapid, preliminary detection of THC, Cocaine, Amphetamine, Methamphetamine, Opiates, Opiates300, PCP, Barbiturates, Benzodiazepines, Methadone, Oxycodone, MDMA, and Tricyclic Antidepressants in human urine. Provides preliminary results only; requires confirmatory testing via GC/MS or HPLC.
Regulatory Classification
Identification
An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.
Special Controls
*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
A. 510(k) Number:
k082898
B. Purpose for Submission:
This submission is for the addition of an over-the-counter (OTC) claim for previously cleared prescription devices: k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104 (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
C. Measurand:
Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (MET), Opiates (OPI), Barbiturates (BAR), Benzodiazepines (BZD), Methadone (MTD), Oxycodone (OXY), MDMA, and Tricyclic Antidepressants (TCA).
D. Type of Test:
Qualitative Lateral Flow Immunoassay
E. Applicant:
Amedica Biotech Inc.
F. Proprietary and Established Names:
Amedica Home Drug Test Cup
G. Regulatory Information:
| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| NGL | II | 862.3650, Test, Opiates, Over-the-Counter | 91 (Tox) |
| NFT | II | 862.3100, Test, Amphetamine, Over-the-Counter | 91 (Tox) |
| NFY | II | 862.3250, Test, Cocaine and Cocaine Metabolites, Over-the-Counter, | 91 (Tox) |
| NGG | II | 862.3610, Test, | 91 (Tox) |
{1}
2
| | | Methamphetamine, Over-the-Counter | |
| --- | --- | --- | --- |
| DIS | II | 862.3120, Enzyme immunoassay, Barbiturate | 91 (Tox) |
| NFV | II | 862.3170, Test, Benzodiazepine, over the counter | 91 (Tox) |
| DJR | II | 862.3620, Enzyme Immunoassay, Methadone | 91 (Tox) |
| LCM | Unclassified [510(k) required] | Unclassified - Enzyme immunoassay, phencyclidine | 91 (Tox) |
| LFG | II | 862.3910, Thin layer chromatography, tricyclic antidepressant drugs | 91 (Tox) |
| NFW | II | 862.3870, Test, Cannabinoids, Over-the-Counter | 91 (Tox) |
## H. Intended Use:
1. Intended use(s):
See indications for use section below.
2. Indication(s) for use:
The Amedica Home Drug Test Cup is an *in vitro* diagnostic test for the rapid detection of the following drugs in human urine.
| Drug | Analyte | Cutoff | Device Code |
| --- | --- | --- | --- |
| Marijuana | THC | 50 ng/mL | THC |
| Cocaine | Benzoylecgonine | 300 ng/mL | COC |
| Amphetamine | Amphetamine | 1000 ng/mL | AMP |
| Methamphetamine | Methamphetamine | 1000 ng/mL | MET |
| Opiates | Morphine | 2000 ng/mL | OPI |
| Opiates300 | Morphine | 300 ng/ml | OPI300 |
| Phencyclidine | Phencyclidine | 25 ng/mL | PCP |
| Barbiturates | Secobarbital | 300 ng/mL | BAR |
| Benzodiazepines | Oxazepam | 300 ng/mL | BZD |
| Methadone | Methadone | 300 ng/mL | MTD |
| Oxycodone | Oxycodone | 100 ng/mL | OXY |
| MDMA | MDMA | 500 ng/mL | MDMA |
| Tricyclic Antidepressants | Nortriptyline | 1000 ng/mL | TCA |
{2}
This test is intended for over-the-counter (OTC) consumer use as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory testing- the second step in the process, is provided in the package labeling.
Tests for prescription drugs will yield preliminary positive results when prescription drugs are ingested, even at or above therapeutic doses. There are no uniformly recognized drug cutoffs for barbiturates, benzodiazepine, and tricyclic antidepressants in urine. The multi-drug of abuse urine test device shows the drug was or was not present at the cutoff level. This test provides only a preliminary result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or High Performance Liquid Chromatography (HPLC) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.
3. Special conditions for use statement(s):
This test is intended for over-the-counter (OTC) consumer use as the first step in a two step process to provide consumers, including but not limited to concerned parents, with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory testing- the second step in the process, is provided in the package labeling.
Tests for prescription drugs will yield preliminary positive results when prescription drugs are ingested, even at or above therapeutic doses. There are no uniformly recognized drug cutoffs for barbiturates, benzodiazepine, and tricyclic antidepressants in urine. The multi-drug of abuse urine test device shows the drug was or was not present at the cutoff level. This test provides only a preliminary result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or High Performance Liquid Chromatography (HPLC) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.
4. Special instrument requirements:
Not applicable (N/A).
I. Device Description:
The Amedica Home Drug Test Cup is a cup capable of measuring all 12 drugs listed in the intended use. The Amedica Home Drug Test Cup also includes user
{3}
instructions, collection device and mailing information for shipping preliminarily positive urine specimens to the laboratory for confirmation.
## J. Substantial Equivalence Information:
1. Predicate device name(s):
Amedica Drug Screen Test Cup
2. Predicate K number(s):
k063379, k061556, k040464, k031497, k023109, k023101, k023104, k023047, k022954 and k022955
3. Comparison with predicate:
The submission is for identical test strips as the predicate devices. The differences are the target population (OTC vs. prescription use) and the number of drugs detected.
## K. Standard/Guidance Document Referenced (if applicable):
None referenced.
## L. Test Principle:
The Amedica Drug Screen Test Cup employs lateral flow immunochromatographic technology and is based on the principle of competitive binding. Drugs, if present in concentrations below the cutoff level, will not saturate the binding sites of antibody-coated particles in the device. The antibody-coated particles will then be captured by immobilized drug-specific conjugate and a colored line will appear in the test line region. The colored line will not form if the sample contains drug in excess of the cutoff level because the drug will saturate all the binding sites of the drug-specific antibody. There is a specific regent strip for each analyte. Each strip in the device contains a procedural control that appears in the control line region indicating that the sample has migrated properly on the test strip.
## M. Performance Characteristics (if/when applicable):
1. Analytical performance:
This submission is for an OTC claim. Performance characteristics for each of the drugs are found in the following 510(k) numbers:: k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104 (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
4
{4}
a. Precision/Reproducibility:
See k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104 (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
b. Linearity/assay reportable range:
See k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104, (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
This device has internal process controls. Each strip in the device contains a procedural control that appears in the control line region indicating that the sample has migrated properly on the test strip. The sponsor informs the user not to interpret the test if a colored line failed to appear in the control region. External controls are not supplied with this device.
d. Detection limit:
See k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104 (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
e. Analytical specificity:
See k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104, (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
f. Assay cut-off:
See k040464 (THC, COC, OPI300, OXY, BAR, BZO), k031497 (MDMA, BAR, BZO, MTD, TCA), k023109 (PCP), k023101 (MTH), k023104 (AMP), k023047 (OPI2000), k022954 (COC) and k022955 (THC).
2. Comparison studies:
a. Method comparison with predicate device:
The sponsor conducted a lay user study with 100 lay persons in three locations: Tennessee, Kentucky and California. Fifty-four females and forty-eight males between 18 and 71 years of age were tested. Fifty-one participants had a high school education or less, forty-eight participants had
{5}
completed college courses. None of the participants had experience with a point of care drug testing product. Each participant was given a pre and post-study questionnaire. The pre-study questionnaire collected personal information about each participant. Test samples were prepared to contain a strong negative (0% of the cutoff), a very weak negative (50% of cutoff), a weak positive (125% of cutoff), a strong positive (150% of cutoff) and a very strong positive (300% of the cutoff) for each drug. The test specimens were prepared at concentrations shown below. Pure drug or metabolite was spiked into drug free human urine. All specimens were verified by GC/MS. 3 users tested six samples, 5 users tested five samples, 92 users tested three samples, one user tested one two samples and one user tested one sample. There were 322 total observations.
| Drug | Cutoff (ng/ml) | Results | Drug Concentration | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | Negative | 50% of C/O | 75% of C/O | 125% of C/O | 150% of C/O | 300% of C/O | Total % correct |
| THC | 50 | Negative | 179 | 19 | 12 | 5 | 0 | 0 | 96% |
| | | Positive | 0 | 0 | 5 | 15 | 18 | 20 | |
| | | Total | 179 | 19 | 17 | 20 | 18 | 20 | |
| | | Agreement | 100% | 100% | 72% | 75% | 100% | 100% | |
| MTD | 50 | Negative | 180 | 19 | 11 | 7 | 0 | 0 | 95% |
| | | Positive | 0 | 0 | 7 | 12 | 17 | 20 | |
| | | Total | 180 | 19 | 18 | 19 | 17 | 20 | |
| | | Agreement | 100% | 100% | 63% | 63% | 100% | 100% | |
| COC | 50 | Negative | 180 | 20 | 12 | 5 | 0 | 0 | 96% |
| | | Positive | 0 | 0 | 5 | 14 | 18 | 19 | |
| | | Total | 180 | 20 | 17 | 19 | 18 | 19 | |
| | | Agreement | 100% | 100% | 72% | 74% | 100% | 100% | |
| BZO | 50 | Negative | 178 | 19 | 14 | 8 | 0 | 0 | 95% |
| | | Positive | 0 | 0 | 6 | 12 | 17 | 19 | |
| | | Total | 178 | 19 | 20 | 20 | 17 | 19 | |
| | | Agreement | 100% | 100% | 70% | 60% | 100% | 100% | |
| OPI | 50 | Negative | 167 | 14 | 7 | 1 | 0 | 0 | 98% |
| | | Positive | 0 | 0 | 3 | 8 | 15 | 16 | |
| | | Total | 167 | 14 | 10 | 9 | 15 | 16 | |
| | | Agreement | 100% | 100% | 70% | 89% | 100% | 100% | |
{6}
| OPI300 | 50 | Negative | 25 | 10 | 7 | 3 | 0 | 0 | 93% |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | Positive | 0 | 0 | 3 | 12 | 15 | 15 | |
| | | Total | 25 | 10 | 10 | 15 | 15 | 15 | |
| | | Agreement | 100% | 100% | 70% | 80% | 100% | 100% | |
| OXY | 50 | Negative | 180 | 19 | 12 | 5 | 0 | 0 | 96% |
| | | Positive | 0 | 0 | 6 | 12 | 20 | 19 | |
| | | Total | 180 | 19 | 18 | 17 | 20 | 19 | |
| | | Agreement | 100% | 100% | 67% | 71% | 100% | 100% | |
| PCP | 50 | Negative | 182 | 19 | 14 | 3 | 0 | 0 | 97% |
| | | Positive | 0 | 0 | 4 | 16 | 18 | 17 | |
| | | Total | 182 | 19 | 18 | 19 | 18 | 17 | |
| | | Agreement | 100% | 100% | 78% | 84% | 100% | 100% | |
| TCA | 50 | Negative | 179 | 19 | 12 | 7 | 0 | 0 | 95% |
| | | Positive | 0 | 0 | 7 | 12 | 18 | 19 | |
| | | Total | 179 | 19 | 19 | 19 | 18 | 19 | |
| | | Agreement | 100% | 100% | 63% | 63% | 100% | 100% | |
| MDMA | 50 | Negative | 176 | 20 | 14 | 5 | 0 | 0 | 96% |
| | | Positive | 0 | 0 | 6 | 14 | 19 | 19 | |
| | | Total | 176 | 20 | 20 | 19 | 19 | 19 | |
| | | Agreement | 100% | 100% | 70% | 74% | 100% | 100% | |
| MET | 50 | Negative | 175 | 20 | 14 | 5 | 0 | 0 | 96% |
| | | Positive | 0 | 0 | 5 | 15 | 20 | 19 | |
| | | Total | 175 | 20 | 19 | 20 | 20 | 19 | |
| | | Agreement | 100% | 100% | 75% | 75% | 100% | 100% | |
| AMP | 50 | Negative | 176 | 20 | 13 | 4 | 0 | 0 | 97% |
| | | Positive | 0 | 0 | 5 | 16 | 19 | 20 | |
| | | Total | 176 | 20 | 18 | 20 | 19 | 20 | |
| | | Agreement | 100% | 100% | 74% | 80% | 100% | 100% | |
| BAR | 50 | Negative | 177 | 20 | 12 | 5 | 0 | 0 | 96% |
| | | Positive | 0 | 0 | 6 | 15 | 18 | 20 | |
| | | Total | 177 | 20 | 18 | 20 | 18 | 20 | |
| | | Agreement | 100% | 100% | 68% | 75% | 100% | 100% | |
A Flesh-Kincaid reading analysis was performed on the package insert and
{7}
the score revealed a reading grade level of 7.4 .
The post-study questionnaire was used to determine if the lay users understood the test instruction and the meaning of the results. Consumers were asked questions about the test, control line and confirmation of results. The results were acceptable. The sponsor conducted a lay-user study to evaluate the temperature strips that are permanently affixed to the Amedica Drug Screen Test Cup. Twenty-one participants between the ages of 18 and 64 years of age tested their own urine samples and recorded what temperature showed up as green on the cup. The participants' results were verified by the professional. All 21 users' results were correct and showed that the users were able to read and understand the affixed temperature strips. Participants were asked questions about how to run the test, ease of use, and how to use the results of the temperature strip. The responses were 100% correct. b.
Matrix comparison:
Not applicable. The assay is intended for urine samples.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
8
{8}
O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
9
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.
